Free to Breathe and the Lung Cancer Mutation Consortium (LCMC) are pleased to announce our collaboration to promote molecular tumor mutation testing for lung cancer patients. The advancement of tumor testing has been recognized by the American Society of Clinical Oncology as one of the keys to developing effective personalized treatments for lung cancer. By understanding the incidence of mutations and other unique traits among different lung cancer tumors, we can better match patients with the specific treatments that are right for them.
The LCMC, formed by 16 cancer centers across the US, marks a clear step forward in making tumor testing available to non-small cell lung cancer patients. By reaching a large population of patients across the country, the LCMC is creating a unique national data set that may help doctors and researchers determine the frequency of certain mutations and explore opportunities for clinical trial enrollment. As we validate known mutations and identify new targets, we’ll build a more thorough understanding of what mutations exist and how to treat the cancers that arise due to them.
The LCMC was initiated with funds available through the American Recovery & Reinvestment Act; with the expiration of these funds, Free to Breathe has assumed the leadership role in managing funds originating from the private sector to allow the LCMC to continue its critical work, expand its reach and enroll more patients.
For more information about the LCMC or to learn about the centers involved, visit www.golcmc.com.
©2017 Free To Breathe | All rights reserved. | Federal tax exempt ID number: 45-0505050.